A5069644872- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Intraperitoneal and Appendiceal Malignancies
- Cancer, Lipids, and Metabolism
- Genetic Associations and Epidemiology
- Cervical Cancer and HPV Research
- Cancer-related molecular mechanisms research
- Endometriosis Research and Treatment
- Ferroptosis and cancer prognosis
- BRCA gene mutations in cancer
- Genetic factors in colorectal cancer
- Monoclonal and Polyclonal Antibodies Research
- Bioinformatics and Genomic Networks
- MicroRNA in disease regulation
- RNA Research and Splicing
- Renal cell carcinoma treatment
- Uterine Myomas and Treatments
- Cancer Genomics and Diagnostics
- Urinary and Genital Oncology Studies
- Clusterin in disease pathology
- 14-3-3 protein interactions
- Cancer Immunotherapy and Biomarkers
- RNA modifications and cancer
- Reproductive Biology and Fertility
- TGF-β signaling in diseases
Rigshospitalet
2010-2020
University of Copenhagen
2010-2020
Copenhagen University Hospital
2007-2017
Duke University Hospital
2011-2016
Duke Medical Center
2011-2016
University of Glasgow
2016
Lunenfeld-Tanenbaum Research Institute
2016
Mount Sinai Hospital
2016
University College London
2016
Radboud University Nijmegen
2016
Risk of malignancy index (RMI), based on a serum cancer antigen 125 level, ultrasound findings and menopausal status, is used to discriminate ovarian from benign pelvic mass. In Denmark, patients with mass RMI ≥200 are referred tertiary gynecologic oncology centers according the national guidelines for treatment. The include recalculation at center and, if indicated, positron emission tomography/computed tomography fast-track surgery by specialists in surgery. aim this study was validate use...
Abstract Purpose: An assay for the single-nucleotide polymorphism (SNP), rs61764370, has recently been commercially marketed as a clinical test to aid ovarian cancer risk evaluation in women with family histories of disease. rs67164370 is 3′-UTR miRNA binding site KRAS oncogene and candidate epithelial (EOC) susceptibility. However, only one published article, analyzing fewer than 1,000 subjects total, examined this association. Experimental Design: Risk association was evaluated 8,669 cases...
Estrogen receptors (ER) status was investigated in 101 primary breast carcinomas and their axillary lymph node metastases to determine if the malignant cells retained or changed this phenotypic feature during metastatic process. Immunohistochemistry with ER‐ICA kit (Abbott Laboratory) on formalin‐fixed paraffin‐embedded tissue used (paraffin ER‐ICA). The ER secondary tumours concordant 80 patients (79%) discordant 21 (21%). Eighteen of these twenty‐one had ER‐positive ER‐negative metastases....
Introduction. In patients with advanced ovarian cancer undergoing preoperative PET/CT, we investigated the prognostic value of SUV in primary tumor and evaluated for predicting incomplete cytoreduction (macroscopic residual tumor). Material methods. From September 2004 to August 2007, 201 consecutive a pelvic Risk Malignancy Index (RMI) > 150 based on serum CA-125, ultrasound examinations menopausal state, underwent PET/CT within two weeks prior standard surgery/debulking tumor. At two-year...
To evaluate the role of 2-deoxy-2-(F)fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) for selecting patients with extensive ovarian cancer (OC) neoadjuvant chemotherapy by evaluating predictors overall survival in stage IIIC/IV OC.From September 1, 2004, to November 20, 2011, 514 consecutive a pelvic tumor underwent preoperative PET/CT; 179 had OC. Patients' characteristics were collected from 153 OC who primary surgery. In 152 OC, clinical and PET/CT...
Abstract Purpose: To determine if the level of apolipoprotein A1, hepcidin, transferrin, inter‐α trypsin IV internal fragment, transthyretin (TT), connective‐tissue activating protein 3 (CTAP3), serum amyloid β‐2 microglobulin (B2M) might have impact on overall and progression‐free survival for ovarian cancer (OC) patients. Experimental design: Serum from 150 OC patients was tested using SELDI‐TOF‐MS. Results: A proteomic prognostic index (xb‐pro) constructed regression coefficients based...
<h3>Objective</h3> To compare clinical demographic and prognostic factors as well overall survival in a nationwide cohort of patients diagnosed with ovarian clear cell carcinoma (oCCC) high grade serous adenocarcinoma (oSAC) during 2005 to 2013. <h3>Materials Methods</h3> Population-based prospectively collected data on oCCC (n = 179) oSAC 2363) cases were obtained from the Danish Gynecological Cancer Database. χ<sup>2</sup>, Fischer or Wilcoxon-Mann-Whitney, multivariate logistic...
High-risk human papillomavirus (HPV) has been suspected to play a role in the carcinogenesis of epithelial ovarian cancer (EOC). However, results from previous studies are conflicting. In most these studies, number tissue samples was small. The current study therefore undertaken examine prevalence high-risk HPV DNA EOC large series patients.Formalin-fixed, paraffin-imbedded tumor 198 cases consecutively included Danish Pelvic Mass Study were analyzed. material 163 serous adenocarcinomas, 15...
The purpose of this study was to develop a novel index for preoperative, non-invasive prediction complete primary cytoreduction in patients with FIGO stage IIIC–IV epithelial ovarian cancer. Prospectively collected clinical data registered the Danish Gynecologic Cancer Database. Blood samples were within 14 days surgery and stored by CancerBiobank. Serum human epididymis protein 4 (HE4), serum cancer antigen 125 (CA125), age, performance status, presence/absence ascites at ultrasonography...